Korro Bio, Inc. KRRO
Korro Bio, Inc. (Nasdaq: KRRO) is a rare genetic drug developer. Its lead program, KRRO-121, is in Pre-clinical for hyperammonemia in urea cycle disorders and hepatic encephalopathy. Its next catalyst on record is KRRO-121: Commence first-in-human trial (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KRRO-121 — Commence first-in-human trial (H2 2026). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| KRRO-110 (REWRITE Phase 1/2a, terminated Q1 2026) | alpha-1 antitrypsin deficiency | oligonucleotide-other | Phase 1 |
| KRRO-121 (GalNAc-REO, glutamine synthetase) | urea cycle disorders; hepatic encephalopathy | oligonucleotide-other | Pre-clinical |
| KRRO-111 (GalNAc-REO) | alpha-1 antitrypsin deficiency | oligonucleotide-other | Pre-clinical |
| Third GalNAc-conjugated program | — | oligonucleotide-other | Pre-clinical |
Recent results and decisions
- Oct 5, 2026started First cohort of healthy volunteers dosed (single 2 mg/kg dose) in the Phase 1/2 ANCHOR trial of RNA-editing oligonucleotide KRRO-121.
Administered a single dose of 2mg/kg to the first cohort of healthy volunteers
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other pre-clinical rare genetic companies
- Abeona Therapeutics Inc. ABEO
- Niagen Bioscience, Inc. Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.